Pharmaceutical and medical device manufacturers have lived with computer system validation (CSV) requirements for decades. The principle is simple: software used in GxP-regulated environments must be validated to demonstrate it does what it's supposed to do, consistently, and that any changes are controlled. The challenge is that AI introduces system behavior that doesn't map cleanly to traditional CSV frameworks, and regulators are actively developing their expectations.

Organizations that wait for final regulatory guidance before addressing AI validation will be caught flat-footed in their next inspection. The ones building documentation and control structures now, under existing frameworks interpreted for AI, will be in a far stronger position when inspectors arrive with specific questions.

Why Traditional CSV Doesn't Fully Apply

Traditional CSV works from a core assumption: given identical inputs and identical system state, the system will always produce identical outputs. This is the foundation of Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). You can test specific scenarios, document expected results, and verify that the system behaves predictably.

AI systems, specifically large language models and machine learning systems used for decision support, quality prediction, or anomaly detection, break this assumption in several ways. Their outputs may vary across identical inputs (non-determinism). Their behavior changes when underlying models are retrained or updated. In some architectures, they incorporate user feedback that continuously shifts their behavior. And their decision-making process is not always interpretable, the system reaches a conclusion, but explaining the specific reasoning path is difficult or impossible.

None of this exempts AI systems from validation requirements. The FDA's existing guidance on software validation (most recently updated in 2022 with the Software as a Medical Device framework) and the EMA's guidance on computerized systems are clear that GxP-impacting software requires demonstrated fitness for intended use. The question is how to demonstrate that fitness for systems with non-deterministic behavior.

The Intended Use Boundary Is Everything

The most important concept for AI systems in GxP environments is precise definition of intended use, and enforcement of the boundary around it. An AI system that supports a quality decision is different from one that makes a quality decision. A predictive maintenance system that flags anomalies for human review is different from one that autonomously initiates process changes. The regulatory risk, validation burden, and control requirements are fundamentally different.

Organizations that want to use AI in regulated environments without the heaviest validation burden should design their systems to stay firmly in the decision support category, the AI identifies, flags, and recommends, while a human with defined qualification makes the GxP decision. This isn't always the right architecture for effectiveness, but it's often the right architecture for the current regulatory environment.

Where AI is making or substantially influencing GxP decisions, the validation requirements scale accordingly. That's not a reason to avoid AI in those roles, but it requires a different level of documentation, testing, and human oversight than decision-support architectures.

What a Validation Package for an AI System Needs to Include

Working from existing CSV frameworks, adapted for AI-specific characteristics, a validation package for a GxP-impacting AI system should address:

Validation Plan. Scope of validation, intended use definition, system boundary, key risks being validated against, acceptance criteria methodology. For AI systems, the validation plan needs to explicitly address how non-determinism is handled, typically through statistical performance criteria rather than exact output matching.

System description and architecture documentation. What model is being used, from what vendor, with what training data? This documentation needs to address the vendor's data handling and model governance practices, because if the vendor changes the underlying model, that's a change event that may require revalidation.

Risk assessment. GxP risk assessment for AI systems should cover not just the system's function but the AI-specific failure modes: hallucination, distributional shift (the system performing differently in production than in validation), bias in training data affecting specific populations, and the consequences of model degradation over time.

Performance qualification testing. For AI systems, PQ typically involves testing against a representative dataset with ground truth labels, establishing statistical acceptance criteria (accuracy, sensitivity, specificity, or task-appropriate metrics), and documenting performance against those criteria. The test dataset needs to be representative of the actual production environment, including edge cases and the populations or scenarios the system will encounter in use.

Change control procedure. This is where many organizations underestimate AI. Model updates, training data changes, and infrastructure changes all require change assessment. Some will require partial or full revalidation. The change control SOP needs to explicitly address AI-specific changes, not just the infrastructure changes that traditional CSV change control handles.

Ongoing monitoring and periodic review. Unlike traditional software that behaves identically unless changed, AI systems can experience performance drift. A quality prediction model trained on historical data may become less accurate as process conditions evolve. An anomaly detection system trained on one plant's data may underperform if deployed across a different site. Monitoring for performance drift, with defined thresholds for remediation, needs to be part of the ongoing lifecycle, not just the initial validation.

The 483 Observation You Don't Want

I've spoken with quality leaders who are unclear on exactly what regulators will ask about their AI systems. Here's the question set that should keep you focused: Can you demonstrate that the AI system was validated for its intended use before deployment? Can you show what validation testing was performed and what the acceptance criteria were? Can you show that the system continues to perform within validated parameters? Can you show that changes to the system, including model updates from the vendor, have been assessed and controlled?

If the answer to any of these is "we're working on it" or "that's handled by the vendor," you have a documentation gap that an inspector will note. AI vendors are not your validation partners, they provide a platform. The validation burden for its use in your GxP environment is yours.

Emerging Regulatory Guidance

Both FDA and EMA have published discussion papers and draft guidance on AI in regulated settings. The FDA's AI/ML Action Plan and the EMA's Reflection Paper on AI provide frameworks for how these agencies are thinking about AI oversight. Neither provides a complete validation methodology, that's still evolving. But both are clear that AI systems in regulated environments require the same foundation of demonstrated fitness for use that all GxP software does.

The ISO 42001 AI management standard provides a governance framework that complements GxP validation requirements, it addresses the organizational processes around AI that FDA and EMA guidance expects to see in place. Organizations implementing ISO 42001 alongside their CSV programs will be better positioned for regulatory scrutiny than those treating AI governance and GxP compliance as separate workstreams.

The organizations that understand they're in the early innings here, that regulators are developing expectations actively and that inspection experience will crystallize requirements, will build documentation structures robust enough to withstand increased scrutiny. The ones waiting for a final rulebook will find it harder to adapt once expectations are settled.